Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Cash from Operations (2016 - 2021)

GT Biopharma (GTBP) has disclosed Cash from Operations for 12 consecutive years, with 3705000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Cash from Operations fell 92.27% to 3705000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was 15606000.0, a 114.9% decrease, with the full-year FY2025 number at 12900000.0, changed 0.03% from a year prior.
  • Cash from Operations was 3705000.0 for Q4 2021 at GT Biopharma, up from 3929000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 223000.0 in Q1 2020 to a low of 4288000.0 in Q2 2021.
  • A 5-year average of 2128411.76 and a median of 1927000.0 in 2020 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 77.26% in 2019, then tumbled 1552.02% in 2021.
  • GT Biopharma's Cash from Operations stood at 2152000.0 in 2017, then tumbled by 96.38% to 4226000.0 in 2018, then skyrocketed by 88.52% to 485000.0 in 2019, then plummeted by 297.32% to 1927000.0 in 2020, then crashed by 92.27% to 3705000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Cash from Operations are 3705000.0 (Q4 2021), 3929000.0 (Q3 2021), and 4288000.0 (Q2 2021).